Upfront Nivolumab/Chemo Produces Durable Responses in Urothelial Carcinoma
February 16th 2024Michiel S. Van der Heijden, MD, PhD, discusses the methods, design, and findings of the phase 3 CheckMate 901 trial of concurrent frontline nivolumab and chemotherapy followed by nivolumab maintenance therapy in urothelial carcinoma.
Watch
Real-World Survival Analysis of Apalutamide vs Enzalutamide in mCSPC
February 14th 2024Neal Shore, MD, FACS, discusses a study aimed to investigate the real-world survival outcomes of men with metastatic castration-sensitive prostate cancer treated with either apalutamide or enzalutamide in the United States.
Watch
Study Links Prior Thymectomy to Higher Rate of Nephrectomy in RCC
February 7th 2024Regina Barragan-Carrillo, MD, discusses findings from a large population-based study which found there to be significantly higher rates of nephrectomy among patients with renal cell carcinoma who had received prior thymectomy vs the incidence of nephrectomy overall.
Watch
Future Directions in the Treatment of Patients With HR+/HER2- Metastatic Breast Cancer
February 5th 2024Virginia Kaklamani, MD, DSc, explains that key unmet needs in HR+/HER2- metastatic breast cancer include overcoming diverse mechanisms of endocrine resistance with genomic profiling and new agents like oral SERDs while managing side effects.
Watch
Management of Adverse Events in Patients With HR+/HER2- Metastatic Breast Cancer
February 5th 2024Virginia Kaklamani, MD, DSc, explains that managing adverse events like fatigue, GI toxicity, and musculoskeletal pain in patients with HR+/HER2- metastatic breast cancer using approaches such as exercise, anti-nausea medication, acupuncture, and supplements is key to meeting the dual treatment goals of prolonging life and maintaining quality of life.
Watch